|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 USD | +1.59% |
|
-3.03% | -25.15% |
ImmunoPrecise Antibodies Ltd. reported earnings results for the full year ended April 30, 2023. For the full year, the company reported sales was CAD 20.67 million compared to CAD 19.36 million a year ago. Net loss was CAD 26.56 million compared to CAD 16.71 million a year ago.
Basic loss per share from continuing operations was CAD 1.07 compared to CAD 0.85 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.15% | 33.68M | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B | |
| -4.33% | 8.5B |
IMMUNOPRECISE ANTIBODIES LTD. 
